Clinical Trials on Protein in China

Total 492 results

First Affiliated Hospital of Fujian Medical University

Recruiting

Value of Chemokine Receptor CXCR4 Imaging for Diagnosis and Prognostic Evaluation in Lymphoproliferative Diseases

Lymphoma | Leukemia | Multiple Myeloma

China
Zhongda Hospital

Recruiting

Study of Efficacy and Safety of Flumatinib Combined With Chemotherapy in Ph Positive ALL

BCR-ABL1 Fusion Protein Expression | Acute Lymphocytic Leukemia, Adult B-Cell

China
First Affiliated Hospital of Zhejiang University
CARsgen Therapeutics Co., Ltd.

Active, not recruiting

Clinical Study of CAR-BCMA T in Patients With Refractory or Relapsed Multiple Myeloma

Refractory or Relapsed Multiple Myeloma

China
The First Affiliated Hospital of Nanchang University

Unknown

Humanized CAR-T Cells of Anti-BCAM and Anti-CD19 Against Relapsed and Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

China
Hebei Yanda Ludaopei Hospital

Unknown

A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

China
Changzhou No.2 People's Hospital

Not yet recruiting

An Clinical Study of NKG2D-CAR-NK Cells for the Treatment of Refractory Recurrent Multiple Myeloma

Multiple Myeloma

China
Jinling Hospital, China

Recruiting

Study on the Efficacy and Safety of Low-dose CTX as Maintenance Therapy for MM Unsuitable for Transplantation

Newly Diagnosed Multiple Myeloma

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Second Affiliated Hospital of Soochow University

Recruiting

UTAA17 Injection in the Treatment of Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma

China
He Huang
Yake Biotechnology Ltd.

Recruiting

A Study of DeepTag-GPRC5D Targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma

Relapse/Refractory Multiple Myeloma

China
Hebei Senlang Biotechnology Inc., Ltd.

Recruiting

the Safety and Efficacy of SENL103 Autologous T Cell Injection

Multiple Myeloma

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

A Study of BCMA CAR-T Cell Therapy for Newly Diagnosed Multiple Myeloma

Multiple Myeloma | New Diagnosis Tumor

China
Second Affiliated Hospital of Xi'an Jiaotong University
Nanjing Legend Biotech Co.

Not yet recruiting

Universal BCMA-targeted LUCAR-B68 Cells in Patients With Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma

China
The First Affiliated Hospital of Soochow University

Withdrawn

An Open Label, Single-arm Clinical Study Evaluating the Safety and Efficacy of ICI201 Infusion in Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma

China
The First Affiliated Hospital of Soochow University
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI346#CIBI346Y001#

Relapsed/Refractory Multiple Myeloma

China
The First Hospital of Jilin University

Unknown

Clinical Trial of Clarithromycin, Lenalidomide and Dexamethasone in the Treatment of the First Relapsed Multiple Myeloma

Multiple Myeloma in Relapse

China
Sun Yat-sen University

Withdrawn

Paclitaxel,Cyclophosphamide and Dexamethasone for Relapsed or Refractory Multiple Myeloma

Relapse/Refractory Multiple Myeloma

China
Sun Yat-sen University

Unknown

CyBorD vs. PAD in the Treatment of Newly Diagnosed Multiple Myeloma

Multiple Myeloma

China
Guangdong Second Provincial General Hospital

Not yet recruiting

To Assess Safety, Tolerability, and Efficacy of Anti-GPRC5D-CD19-CAR-T in Relapsed/Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

A Study of BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma

Refractory Multiple Myeloma | Relapse Multiple Myeloma

China
The First Affiliated Hospital of Soochow University
CARsgen Therapeutics Co., Ltd.

Recruiting

A Study to Access the Safety and Efficacy of CT0590 in Patients With Relapsed and/or Refractory Multiple Myeloma

Relapsed and/or Refractory Multiple Myeloma

China
Hebei Senlang Biotechnology Inc., Ltd.

Recruiting

CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

China
Sun Yat-sen University

Recruiting

VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma

Myeloma | Newly Diagnosed | High Risk

China
Nanfang Hospital of Southern Medical University
Guangzhou First People's Hospital; Sun Yat-Sen Memorial Hospital of Sun Yat-Sen... and other collaborators

Unknown

Mel vs BUCY+VP-16 Conditioning Regimen for MM Undergoing Auto-HSCT

Multiple Myeloma | Conditioning | Autologous Hematopoietic Stem Cell Transplantation

China
The First Affiliated Hospital with Nanjing Medical...

Unknown

A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

China
Sun Yat-sen University
China Food and Drug Administration

Withdrawn

Clarithromycin,Lenalidomide and Dexamethasone for Relapsed/Refractory Myeloma

Relapse/Refractory Multiple Myeloma

China
Shanghai Public Health Clinical Center
Merck Sharp & Dohme LLC

Unknown

Efficacy and Safety of MK-0518 in Treatment-Experienced HIV-1 Infected Adult Patients With Hemophilia

HIV Infection | Hemophilia A

China
GlaxoSmithKline

Completed

A Study of Belantamab Mafodotin to Investigate Safety, Tolerability, Pharmacokinetics, Immunogenicity and Clinical Activity in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

Multiple Myeloma

China
Shenzhen Geno-Immune Medical Institute

Unknown

Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma

Multiple Myeloma

China
Hebei Senlang Biotechnology Inc., Ltd.
Hebei Yanda Ludaopei Hospital; Beijing Lu Daopei Hospital

Unknown

Immunotherapy With BCMA CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

China
RenJi Hospital

Recruiting

Id and Rd Maintenance Regimens After Induction of Remission in Multiple Myeloma.

Overall Survival | Progression Free Survival | Maintenance

China
Chunrui Li
Nanjing IASO Biotherapeutics Co.,Ltd

Recruiting

A Study of a Fully Human BCMA-targeting CAR (CT103A) Combined With Selinexor in Patients With Relapsed/Refractory Extramedullary Multiple Myeloma

Extramedullary Multiple Myeloma

China
Sun Yat-sen University

Unknown

The Efficacy and Safety of Pomalidomide and Bendamustine With Dexamethasone in Relapsed or Refractory Multiple Myeloma

Relapsed, Refractory, Multiple Myeloma

China
Chunrui Li
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI346#CIBI346Y002#

Relapsed/Refractory Multiple Myeloma

China
The First Affiliated Hospital of Xiamen University

Recruiting

All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory

China
Shandong New Time Pharmaceutical Co., LTD

Recruiting

Phase 1 Study of F182112 in Patients With Relapsed or Refractory Multiple Myeloma

Dose-Escalation Study, Relapsed or Refractory Multiple Myeloma

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory

China
Chongqing Precision Biotech Co., Ltd

Recruiting

BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma

Multiple Myeloma | Multiple Myeloma in Relapse | Neoplasm, Plasma Cell

China
Qianfoshan Hospital

Not yet recruiting

Neutrophil-to-lymphocyte and Platelet-to-lymphocyte Ratio in Predicting the Incidence of Nausea and Vomiting

Hemophilia A

China
The First Affiliated Hospital of Soochow University

Recruiting

This is an Open-label, Single Arm Study to Evaluate the Safety and Tolerability of Treatment With CT0591CP in Patients With Relapsed and/or Refractory Multiple Myeloma.

Relapsed and/or Refractory Multiple Myeloma

China
Wuhan Union Hospital, China
Wuhan Si'an Medical Technology Co., Ltd

Recruiting

T Cells Expressing a Bispecific CAR Targeting CS1 and BCMA in Relapsed/Refractory Multiple Myeloma

CS1+ or BCMA+ Multiple Myeloma

China
HitGen Inc.

Terminated

A Study of HG146 Capsule in Chinese Subjects With Relapsed and Refractory Multiple Myeloma

Multiple Myeloma | Relapsed and Refractory Multiple Myeloma

China
Second Affiliated Hospital of Xi'an Jiaotong University
Nanjing Legend Biotech Co.

Unknown

LCAR-B4822M-02 Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma

Refractory or Relapsed Multiple Myeloma

China
The Pregene (ShenZhen) Biotechnology Company, Ltd.
Henan Cancer Hospital

Unknown

BCMA Nano Antibody CAR-T Cells for Patients With Refractory and Relapsed Multiple Myeloma (BCMA CAR-T)

Relapsed and Refractory Multiple Myeloma

China
The First Affiliated Hospital of Soochow University

Unknown

Study of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients With Multiple Myeloma in China (MM)

Multiple Myeloma Proved by Laboratory Tests

China
The First Affiliated Hospital of Soochow University
CARsgen Therapeutics Co., Ltd.

Recruiting

CT0594CP CAR-T Cells in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

Multiple Myeloma | Plasma Cell Leukemia

China
Zhejiang University
Hangzhou Cheetah Cell Therapeutics Co., Ltd

Recruiting

BCMA CAR-NK For Patients With RRMM

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory

China
920th Hospital of Joint Logistics Support Force...

Recruiting

Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory

China
Chongqing Precision Biotech Co., Ltd

Enrolling by invitation

Dual-target CAR-T Cells (C-4-29) in the Treatment of Relapsed/Refractory Multiple Myeloma

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory

China
Shanghai Zhongshan Hospital

Recruiting

The China M-protein Screening Project in First-degree Relatives of Myeloma Patient - The CHAPERONE Study (CHAPERONE)

Multiple Myeloma | Monoclonal Gammopathy of Undetermined Significance

China
Shanghai Changzheng Hospital
CARsgen Therapeutics Co., Ltd.

Recruiting

Study of CT071 Injection in RRMM or PPCL

Multiple Myeloma | Primary Plasma Cell Leukemia

China

Clinical Trials on Protein in China

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cameroon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations